vimarsana.com

Latest Breaking News On - Igor astsaturov - Page 1 : vimarsana.com

Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th with the first webinar on the increasing prevalence of non-small cell lung cancer in.

United statesAr riyaSaudi arabiaKishor bhatiaTesaro glaxosmithklineIgor astsaturovPaulf engstromReggie ewesuedoCare at fox chase cancer centerDepartment of hematology oncologyOhio state universitySecurities exchangeChildren cancer center riyadhMalignancy programLantern pharma incDepartment of hematology

The End of Pancreatic Cancer Could Be Just Around the Corner

Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.

United statesTreasure islandTemple universityFox chase cancer centerIgor astsaturovPaulf engstromAmerican cancer societyTemple university health systemCurrent optionsPancreatic cancer treatment don tPotential endLantern pharmaAmerican cancerStatpearls publishingProstaglandin reductaseSynthetic lethal

Dr Igor Astsaturov Appointed Inaugural Holder of Paul F Engstrom Professorship in Oncology at Fox Chase Cancer Center

Igor Astsaturov, MD, PhD, has been appointed inaugural holder of the Paul F. Engstrom Professorship in Oncology.

Fox chase cancer centerUnited statesFox chaseJonathan chernoffRobert uzzoIgor astsaturovPaulf engstromDepartment of hematology oncologyCancer centerInstitute for cancer researchAssociate professorConcetta greenberg pancreatic cancer instituteCancer center directorTop doctorEngstrom professorshipAmerican oncologic hospital

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

14.09.2022 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ( A.I. ) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery . Seite 1

Igor astsaturovDrug administrationConcetta greenberg pancreatic cancer instituteFox chase cancer centerOrphan drug designationRare pediatricDisease designationLantern pharma

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights

/PRNewswire/ Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform.

United statesDavid waldmanIgor astsaturovNicholas koulermosKishorg bhatiaJohns hopkins universityExchange commission onCrescendo communicationsDrug administrationExchange commissionLantern pharma incSecurities exchangeSociety of neuro oncologyPanna sharmaLantern pharmaSubsequent highlights

vimarsana © 2020. All Rights Reserved.